Log in
Enquire now
‌

US Patent 12122834 Anti-PD-1 antibodies

Patent 12122834 was granted and assigned to Merck Sharp & Dohme Limited on October, 2024 by the United States Patent and Trademark Office.

OverviewStructured DataIssuesContributors
Is a
Patent
Patent
0
Current Assignee
Merck Sharp & Dohme Limited
Merck Sharp & Dohme Limited
0
Date Filed
January 31, 2019
0
Date of Patent
October 22, 2024
0
Patent Applicant
Merck Sharp & Dohme Limited
Merck Sharp & Dohme Limited
0
Patent Application Number
16965616
0
Patent Citations
‌
US Patent 10188730 Anti-LAG3 antibodies and antigen-binding fragments
0
‌
US Patent 11136408 Anti-PD-1 antibodies, method for producing same and method for using same
0
‌
US Patent 11072658 Anti-PD-1/LAG3 bispecific antibodies
0
‌
US Patent 7029872 Methods for producing modified glycoproteins
0
‌
US Patent 7449308 Combinatorial DNA library for producing modified N-glycans in lower eukaryotes
0
‌
US Patent 8354509 Antibodies to human programmed death receptor PD-1
0
‌
US Patent 8592562 Method for making antibody Fc-heterodimeric molecules using electrostatic steering effects
0
‌
US Patent 9248181 Methods and means for the production of Ig-like molecules
0
Patent Inventor Names
Veronica Juan
0
Shaopeng Huang
0
Laurence Fayadat-Dilman
0
Hua Ying
0
Shireen Khan
0
Patent Jurisdiction
United States Patent and Trademark Office
United States Patent and Trademark Office
0
Patent Number
12122834
0
Patent Primary Examiner
‌
Lynn A Bristol
0
CPC Code
‌
C07K 2317/565
0
‌
C07K 2317/24
0
‌
C07K 16/2818
0

Find more entities like US Patent 12122834 Anti-PD-1 antibodies

Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.
Open Query Tool
Access by API
Golden Query Tool
Golden logo
By using this site, you agree to our Terms of Service.